^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Thymoma

    Related cancers:
    Apply
    A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (NCT03076554)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/19/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    PD-L1
    |
    Bavencio (avelumab)
    Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI) (NCT04710628)
    Phase 2
    MedSIR
    Active, not recruiting
    Last update posted :
    08/08/2024
    Initiation :
    09/21/2021
    Primary completion :
    07/01/2024
    Completion :
    01/31/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    IL-8+ naïve T Cells as a Biomarker for Thymoma Identification (NCT05255965)
    Phase N/A
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    09/01/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    CXCL8
    177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP) (NCT04375267)
    Phase 1
    Vastra Gotaland Region
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    04/23/2020
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    SSTR
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    Application of 68Ga-Pentixafor PET/CT for Thymoma (NCT06086327)
    Phase 1
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    10/17/2023
    Initiation :
    06/22/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    CXCR4
    |
    CXCR4 expression
    Molecular Analysis of Thoracic Malignancies (NCT01385722)
    Phase N/A
    Stanford University
    Enrolling by invitation
    Last update posted :
    07/19/2023
    Initiation :
    08/01/2011
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF
    Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NCT03134118)
    Phase 2
    European Organisation for Research and Treatmen...
    Active, not recruiting
    Last update posted :
    02/21/2023
    Initiation :
    04/11/2018
    Primary completion :
    12/01/2023
    Completion :
    07/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) (NCT03517488)
    Phase 1
    Xencor, Inc.
    Completed
    Last update posted :
    12/01/2022
    Initiation :
    07/10/2018
    Primary completion :
    06/01/2022
    Completion :
    09/06/2022
    HER-2 • ER • PGR • MSI
    |
    MSI-H/dMMR • HER-2 negative
    |
    vudalimab (XmAb717)
    Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (NCT02049047)
    Phase 2
    Armando Santoro, MD
    Completed
    Last update posted :
    09/10/2022
    Initiation :
    02/01/2011
    Primary completion :
    04/01/2014
    Completion :
    01/01/2019
    PTEN • mTOR
    |
    everolimus
    Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma (NCT04554524)
    Phase 4
    Tang-Du Hospital
    Recruiting
    Last update posted :
    10/28/2020
    Initiation :
    08/27/2020
    Primary completion :
    07/30/2024
    Completion :
    07/30/2024
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel
    Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases (NCT02948855)
    Phase N/A
    Tianjin Medical University Cancer Institute and...
    Withdrawn
    Last update posted :
    05/18/2018
    Initiation :
    10/01/2016
    Primary completion :
    05/01/2018
    Completion :
    05/01/2018
    NOTCH2